Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

New chemotherapy agents improve survival time for patients with metastatic colorectal cancer

New chemotherapy agents appear associated with improvements in survival time for patients with metastatic colorectal cancer but at substantial cost.

17 Mar 2010

Radiofrequency ablation helps prolong life of colorectal cancer patients

Approximately half of Americans living with colorectal cancer will develop liver metastases at some point during the course of their disease. Radiofrequency ablation, a minimally invasive treatment that applies heat directly in the tumor causing cancer cell death with minimal associated injury to the surrounding healthy liver, contributes to prolongation of their life by nearly three years, note researchers at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa, Fla.

17 Mar 2010

Colon cancer patients often not treated with recommended level of chemotherapy

New results from a major initiative on the quality of cancer care in the United States show that patients with a common type of colon cancer -- especially older patients -- often are not treated as aggressively with chemotherapy as research shows is necessary to improve survival.

17 Mar 2010

NCCN Guidelines translated into Japanese

The NCCN Clinical Practice Guidelines in Oncology have been further recognized as the global standard in oncology with the announcement that select NCCN Guidelines™ are being translated into Japanese. The Translational Research Informatics Center Foundation for Biomedical Research and Innovation, under the supervision of the Japanese Society for Cancer of the Colon and Rectum, has translated the NCCN Guidelines for Colon Cancer and Rectal Cancer, which are now available online.

17 Mar 2010

Key cellular defect in protein synthesis can lead to cancer susceptibility

UCSF researchers have discovered that a key cellular defect that disturbs the production of proteins in human cells can lead to cancer susceptibility. The scientists also found that a new generation of inhibitory drugs offers promise in correcting this defect.

17 Mar 2010

Levels of perceived cancer risk can affect health and longevity

Mammograms, pap smears and early detection tests for prostate cancer, colorectal cancer and other malignancies are critical for catching cancer before it becomes deadly.

16 Mar 2010

Stage IV colorectal cancer: Therapy that improves overall survival over IFL/bevacizumab will earn 60% patient share

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a therapy that would improve median overall survival over IFL (bolus 5-fluorouracil, generics/leucovorin, generics/irinotecan*) plus bevacizumab (Roche/Genentech/Chugai's Avastin), would earn a 60 percent patient share in stage IV colorectal cancer, according to surveyed U.S. oncologists. In Europe, such an agent would earn a 50 percent patient share, according to surveyed European oncologists.

16 Mar 2010

Gene defects could become targets for new personalised treatments for bowel cancer

Cancer Research UK-funded scientists have discovered that the gene defects that cause some bowel cancers could become the targets for new personalised treatments. Their research is published in Cancer Cell today (Monday).

16 Mar 2010

Latest treatment options for colorectal cancer highlighted at NCCN Annual Conference

Despite statistics stating that colorectal cancer is the fourth most frequently diagnosed cancer in men and women in the United States, mortality from colon cancer has decreased slightly over the past 30 years, possibly because of earlier diagnoses through screening and better treatment modalities.

15 Mar 2010

Pro-Pharmaceuticals reports net loss applicable to common stock of $1.3M for fourth-quarter 2009

Pro-Pharmaceuticals, Inc., a developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today reported its financial results for full year and fourth quarter, ended December 31, 2009. These results are included in the Company’s Annual Report on Form 10-K which has been filed with the SEC.

12 Mar 2010

Vermont: Only state to pass bill mandating coverage of colon cancer screening

Progress towards nationwide, state-mandated coverage of colon cancer screening according to accepted medical guidelines has slowed to a crawl as state legislators await the outcome of the health care reform debate at the federal level, a coalition of public health associations and medical professional societies reported today. With a better grade for only a single state – Vermont – 2009 marks the least improvement in a single year since the Colorectal Cancer Legislation Report Card began in 2004.

12 Mar 2010

Pro-Pharmaceuticals announces closing of $335,000 tranche of private placement

Pro-Pharmaceuticals, Inc., today announced that it has closed a $335,000 tranche of a private placement of up to $6.0 million with 10X Fund, L.P., which is purchasing unregistered Series B convertible preferred stock and warrants. This tranche brings the total raised to date from the 10X Fund to approximately $5.1 million.

11 Mar 2010

InvestorSoup.com announces investment report featuring Exact Sciences

InvestorSoup.com announces an investment report featuring Exact Sciences Corp. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

11 Mar 2010

Eureka Genomics announces closing of $3.7M private financing round

Eureka Genomics today announced the closing of a $3.7 million private financing round whose participants included private individuals and undisclosed angel investors. The proceeds will further discovery research aimed at identifying novel microorganisms associated with specific cancers and other important diseases, as well as help grow Eureka Genomics’ high-throughput sequencing and bioinformatics service business on a global basis.

11 Mar 2010

Idera Pharmaceuticals announces net income of $3.9M for fourth-quarter 2009

Idera Pharmaceuticals, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2009.

10 Mar 2010

Campaign to Stop Colon Cancer Now launched in conjunction with National Colorectal Cancer Awareness Month

The Campaign to Stop Colon Cancer Now, a campaign to increase screenings and prevent the nation's second-leading cancer killer, launched today in conjunction with National Colorectal Cancer Awareness Month in March.

10 Mar 2010

IBS patients are at no greater risk of having polyps, colon cancer than healthy people undergoing colonoscopies

Patients with irritable bowel syndrome are at no greater risk of having polyps, colon cancer or inflammatory bowel diseases than healthy people undergoing colonoscopies, according to new research published in the American Journal of Gastroenterology.

10 Mar 2010

Nanoparticles: Targeted cancer therapy

Another weapon in the arsenal against cancer: Nanoparticles that identify, target and kill specific cancer cells while leaving healthy cells alone.

9 Mar 2010

Viatronix V3D-Colon software used for the President's colon cancer screening exam

Viatronix Incorporated, a Stony Brook, New York, based company announced that its V3D-Colon software is used at the National Naval Medical Center where the President's annual physical was done. "Our software is being utilized at several DOD facilities since the landmark Virtual Colonoscopy clinical trial published in the New England Journal of Medicine back in December 2003," said Zaffar Hayat, President of Viatronix Incorporated.

9 Mar 2010

Poniard Pharmaceuticals reports net loss of $13.2M for fourth-quarter 2009

Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today reported financial results for the fourth quarter and year ended December 31, 2009.

8 Mar 2010

Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

New chemotherapy agents improve survival time for patients with metastatic colorectal cancer

Radiofrequency ablation helps prolong life of colorectal cancer patients

Colon cancer patients often not treated with recommended level of chemotherapy

NCCN Guidelines translated into Japanese

Key cellular defect in protein synthesis can lead to cancer susceptibility

Levels of perceived cancer risk can affect health and longevity

Stage IV colorectal cancer: Therapy that improves overall survival over IFL/bevacizumab will earn 60% patient share

Gene defects could become targets for new personalised treatments for bowel cancer

Latest treatment options for colorectal cancer highlighted at NCCN Annual Conference

Pro-Pharmaceuticals reports net loss applicable to common stock of $1.3M for fourth-quarter 2009

Vermont: Only state to pass bill mandating coverage of colon cancer screening

Pro-Pharmaceuticals announces closing of $335,000 tranche of private placement

InvestorSoup.com announces investment report featuring Exact Sciences

Eureka Genomics announces closing of $3.7M private financing round

Idera Pharmaceuticals announces net income of $3.9M for fourth-quarter 2009

Campaign to Stop Colon Cancer Now launched in conjunction with National Colorectal Cancer Awareness Month

IBS patients are at no greater risk of having polyps, colon cancer than healthy people undergoing colonoscopies

Nanoparticles: Targeted cancer therapy

Viatronix V3D-Colon software used for the President's colon cancer screening exam

Poniard Pharmaceuticals reports net loss of $13.2M for fourth-quarter 2009

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in